<DOC>
	<DOCNO>NCT00455520</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness ( level pain control ) safety Tapentadol ( CG5503 ) extend release ( ER ) ( base ) compare placebo patient moderate severe pain diabetic peripheral neuropathy .</brief_summary>
	<brief_title>A Safety Efficacy Study Tapentadol ( CG5503 ) Extended Release Patients With Painful Diabetic Peripheral Neuropathy</brief_title>
	<detailed_description>The primary objective randomized-withdrawal ( randomize mean study medication assign patient chance withdrawal mean stop use ) , multicenter , double-blind ( neither patient investigator know study medication ) , placebo-controlled , Phase 3 study determine effectiveness safety orally administrate Tapentadol ( CG5503 ) extend release ( ER ) ( base ) dose 100-250 mg twice daily patient moderate severe pain diabetic peripheral neuropathy . The study conduct registration approval CG5503 US outside US . The trial consist two phase : Phase I open-label Phase 2 double- blind . In Open-Label Phase 1 four period : screening ( assess eligibility ) , washout ( dependent pain medication patient previously take ) , pain intensity perctoris evaluation ( 3 day period ) , open-label titration ( study drug titrate optimal dose start 50 mg twice day adjust optimal dose period 3 week ) . Patients least 1-point reduction average pain intensity score end open-label titration period , compare pre-titration eligible randomization double-blind phase . In double-blind Phase 2 , two period : double-blind maintenance period ( take drug 12 week ) , follow-up ( visit within 4 day intake last dose study drug follow-up call approximately 10-14 day intake last dose study drug ) . The patient maintain dose level achieve end Phase 1 double-blind treatment phase . The study hypothesis study drug different placebo change pain intensity . Titrate Tapentadol ( CG5503 ) extend release ( ER ) 50 mg patient 's optimal dose range 100mg 250mg twice day ; Placebo ( active ingredient ) . All dose trial treatment take orally without food , maximum timeframe 15 week .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Patients Type 1 Type 2 diabetes mellitus must document clinical diagnosis painful diabetic peripheral neuropathy symptom sign least 6 month , pain present time screen The investigator consider patient 's blood glucose control diet , hypoglycemics , insulin least 3 month prior enrol study ( control document figure glycated hemoglobin [ HbA1c ] great 11 % screening ) Patients take analgesic medication condition least 3 month prior screen ( patient take opioid analgesic must dissatisfy current treatment , patient take nonopioid analgesic must dissatisfy current analgesia ) Patients currently require opioid treatment must take daily dos opioidbased analgesic equivalent &lt; =160 mg oral morphine No significant pulmonary , gastrointestinal , endocrine , metabolic ( except diabetes mellitus ) , neurological , psychiatric disorder ( result disorientation , memory impairment inability report accurately schizophrenia , Alzheimer 's disease ) , clinically significant disease Investigator 's opinion may affect efficacy safety assessment may compromise patient 's safety trial participation history moderate severe hepatic impairment chronic hepatitis B C , presence active hepatitis B C within last 3 month impair hepatic function ALT AST great 3fold ULN No patient severely impaired renal function No laboratory value limit normal unless consider clinically relevant Investigator No significant cardiac disease ( e.g. , unstable angina pectoris , angina pectoris Canadian Cardiovascular Society ( CCS ) class IIIIV , acute myocardial infarction within last 3 month , cardiac insufficiency New York Heart Association ( NYHA ) class IIIIV ) significant vascular disease ( e.g. , peripheral arterial occlusive disease ( PAOD ) Fontaine class IIbIV ) lifelong history seizure disorder epilepsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Diabetic neuropathy</keyword>
	<keyword>Painful Diabetic Polyneuropathy</keyword>
	<keyword>Polyneuropathy</keyword>
	<keyword>Peripheral neuropathy</keyword>
</DOC>